Inspyr Therapeutics, Inc. Appoints Richard Buller to Board of Directors
October 13, 2016 at 04:30 pm IST
Share
Inspyr Therapeutics, Inc. announced the appointment of Richard Buller, M.D., Ph.D. to its Board of Directors. Richard Buller, M.D., Ph.D. has over 25 years of experience leading the development of novel oncology products, resulting in 15 regulatory submissions for 8 oncology drug products as well as 2 premarketing approvals for companion diagnostics. In his most recent positions, Dr. Buller served initially as Vice President of Translational Oncology, adding a brief role as Interim Head of Late-Stage Clinical Development, and then became Pfizer’s Head of Oncology Clinical Development. Previously, he was Vice President, Translational Medicine for Exelixis and was a member of the Joint Development Committees with partners Bristol Myers Squibb and Sanofi Aventis.
Rebus Holdings, Inc. is a pharmaceutical company. The Company is focused on the research and development of targeted precision therapeutics for the treatment of cancer. The Company utilizes its proprietary delivery technology to enhance immuno-modulation for developing therapeutic outcomes. Its immune-oncology lead asset, RT-AR001, is an adenosine A2A receptor antagonist, is differentiated by its intratumoral delivery of nano- or microparticle formulations that allow for better tumor infiltration. Its patented portfolio of adenosine receptor antagonists provides treatment based on the specific adenosine targets found in each type of cancer. The adenosine receptor modulators include A2A, A2B and dual A2A/A2B antagonists, that have broad development applicability, including indications within immuno-oncology. It is also engaged in the manufacturing of platform delivery systems for nano- or microparticle formulations that are used in toxicology studies.
REBUS HOLDINGS, INC. 
